Effect of Donor Diabetes and Other Factors on Corneal Transplant Endothelial Cell Loss and Success at 5 Years
Part of paid clinical trials in Atlanta, Georgia.
- Sponsor
- Case Western Reserve University
- Study ID
- NCT07217249
- Status
- Enrolling By Invitation
Conditions
- Corneal Endothelial Decompensation
- Fuchs Endothelial Corneal Dystrophy
Eligibility Criteria
- Sex
- ALL
- Age
- 30 Years - 93 Years
- Healthy Volunteers
- Not accepted
Interventions
- Descemet membrane endothelial keratoplasty — PROCEDUREReplacement of the recipient corneal endothelial and Descemet membrane with healthy tissue from a donor cornea.
Study Details
This multi-center clinical trial is designed to assess the association of diabetes in a cornea donor with transplant success and loss of endothelial cells 5 years following Descemet membrane endothelial keratoplasty (DMEK). Study eyes are assigned to receive either a cornea from a donor without diabetes or a cornea from a donor with diabetes in a masked fashion.
Key Dates
- Start date
- Dec 3, 2025
- Status verified
- Feb 2026
- Primary completion
- Dec 30, 2029
- Completion
- Apr 30, 2030
Study Design
- Enrollment
- 570 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Assigned cornea from a donor without diabetesEyes assigned to this arm receive a cornea from a donor without diabetes and undergo Descemet membrane endothelial keratoplasty.
- Active Comparator: Assigned cornea from a donor with diabetesEyes assigned to this arm receive a cornea from a donor with diabetes for Descemet membrane endothelial keratoplasty.
Primary Outcome Measure
Change in central corneal endothelial cell density 5 years after Descemet membrane endothelial keratoplasty. [ Time Frame: Subjects are followed for 5 years after corneal transplantation. ]
Locations (14)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Georgia Eye Partners | Atlanta | Georgia | 30189 | - |
| Price Vision Group | Indianapolis | Indiana | 46260 | - |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | - |
| Kansas City Eye Clinic | Overland Park | Kansas | 66204 | - |
| Mid-Atlantic Cornea Consultants | Baltimore | Maryland | 21204 | - |
| The Wilmer Eye Institute/Johns Hopkins | Baltimore | Maryland | 21287 | - |
| University of Michigan/Kellogg Eye Center | Ann Arbor | Michigan | 48105 | - |
| Verdier Eye Center | Grand Rapids | Michigan | 49546 | - |
| Minnesota Eye Consultants | Bloomington | Minnesota | 55431 | - |
| Mayo Clinic | Rochester | Minnesota | 55905 | - |
| Associated Eye Care | Stillwater | Minnesota | 55082 | - |
| Moyes Eye Center | Kansas City | Missouri | 64154 | - |
| Legacy Devers Eye Institute | Portland | Oregon | 97210 | - |
| Ophthalmic Partners | Bala-Cynwyd | Pennsylvania | 19004 | - |
Find similar trials in Atlanta, GA
Related Studies
- DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal DystrophyPHASE2 · Recruiting · Design Therapeutics, Inc. · Indianapolis, Indiana
- Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal DystrophyPHASE2 · Recruiting · Massachusetts Eye and Ear Infirmary · Boston, Massachusetts